DGIdb - REPAGLINIDE Drug Record

REPAGLINIDE chembl:CHEMBL1272 Approved

Alternate Names:

NOVONORM
AG-EE 623 ZW
ENYGLID
AG-EE-623-ZW
AG-EE-623ZW
A10BX02
REPAGLINIDE
AGEE-623ZW
PRANDIN
REPAGLINIDA
(-)-REPAGLINIDE
REPAGLINIDUM
PRANDIN®
SUREPOST
AG-EE 388 ZW
pubchem.compound:65981
rxcui:73044
chembl:CHEMBL1272
drugbank:00912
chemidplus:135062-02-1

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidiabetic
Drug Class	hypoglycemic agents
Year of Approval	1997

(3 More Sources)

Publications:

Rodríguez-Antona C et al., 2008, Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism., Pharmacogenomics J
Niemi M et al., 2003, Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide., Clin Pharmacol Ther
Tomalik-Scharte D et al., 2011, Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide., Drug Metab Dispos
Tornio A et al., 2008, The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo., Clin Pharmacol Ther
Niemi M et al., 2005, Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics., Clin Pharmacol Ther
Yu M et al., 2010, KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes., Clin Pharmacol Ther
Hu et al., 2000, Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide., J. Pharmacol. Exp. Ther.
Wängler et al., 2004, Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET)., Nucl. Med. Biol.
Hansen et al., 2002, Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1., Diabetes
Wängler et al., 2004, Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent., Bioorg. Med. Chem. Lett.
Sunaga et al., 2001, The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide., Eur. J. Pharmacol.
Dornhorst, 2001, Insulinotropic meglitinide analogues., Lancet
Du QQ et al., 2013, PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers., Eur J Clin Pharmacol
Huang Q et al., 2010, Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients., Eur J Clin Pharmacol
Dai XP et al., 2012, KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol

REPAGLINIDE SLC30A8

Interaction Score: 8.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20809084

Sources:
PharmGKB
REPAGLINIDE IGF2BP2

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
REPAGLINIDE ABCC8

Interaction Score: 2.18

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name repaglinide,Prandin, NovoNorm, PrandiMet

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

PMIDs:
10773014 15219283 12196472 15380228 11716850 11728565

Sources:
TdgClinicalTrial ChemblInteractions TTD
REPAGLINIDE PAX4

Interaction Score: 2.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
REPAGLINIDE TCF7L2

Interaction Score: 1.65

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20054294

Sources:
PharmGKB
REPAGLINIDE NEUROD1

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
REPAGLINIDE CYP2C8

Interaction Score: 0.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17923851 14534525 21270106 18388877 15961978

Sources:
PharmGKB
REPAGLINIDE NOS1AP

Interaction Score: 0.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
REPAGLINIDE KCNQ1

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22414228

Sources:
PharmGKB
REPAGLINIDE KCNJ11

Interaction Score: 0.59

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

Direct Interaction yes

PMIDs:
20054294

Sources:
ChemblInteractions TEND PharmGKB
REPAGLINIDE ABCC9

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
REPAGLINIDE KCNJ1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
REPAGLINIDE NR1I2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23807564

Sources:
PharmGKB
REPAGLINIDE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
REPAGLINIDE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TEND: REPAGLINIDE
- Version: 01-August-2011
Alternate Names:

REPAGLINIDE Primary Drug Name

Drug Info:

Year of Approval 1997

Drug Class hypoglycemic agents

Publications:
TdgClinicalTrial: REPAGLINIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: repaglinide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Huang Q et al., 2010, Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients., Eur J Clin Pharmacol

Yu M et al., 2010, KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes., Clin Pharmacol Ther

Dai XP et al., 2012, KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol

DTC: REPAGLINIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL1272 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Repaglinide
- Version: 2020.06.01
Alternate Names:

D0N5YA TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1272
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1272
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	repaglinide,Prandin, NovoNorm, PrandiMet
Mechanism of Interaction	Sulfonylurea receptor 1, Kir6.2 blocker

Mechanism of Interaction	Sulfonylurea receptor 1, Kir6.2 blocker
Direct Interaction	yes

blocker (inhibitory)
inhibitor (inhibitory)

REPAGLINIDE Drug Record

REPAGLINIDE chembl:CHEMBL1272 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20809084

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name repaglinide,Prandin, NovoNorm, PrandiMet Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

PMIDs: 10773014 15219283 12196472 15380228 11716850 11728565

Sources: TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20054294

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17923851 14534525 21270106 18388877 15961978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22414228

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker Direct Interaction yes

PMIDs: 20054294

Sources: ChemblInteractions TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23807564

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

TEND: REPAGLINIDE

Alternate Names: REPAGLINIDE Primary Drug Name

Drug Info: Year of Approval 1997 Drug Class hypoglycemic agents

Publications:

TdgClinicalTrial: REPAGLINIDE

Alternate Names:

Drug Info: Drug Indications antidiabetic Drug Class Small Molecule FDA Approval approved

Publications:

PharmGKB: repaglinide

Alternate Names:

Drug Info:

DTC: REPAGLINIDE

Alternate Names: CHEMBL1272 ChEMBL Drug ID

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
20809084

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name repaglinide,Prandin, NovoNorm, PrandiMet

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

PMIDs:
10773014 15219283 12196472 15380228 11716850 11728565

Sources:
TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20054294

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17923851 14534525 21270106 18388877 15961978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22414228

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

Direct Interaction yes

PMIDs:
20054294

Sources:
ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND

Interaction Types & Directionality:

n/a

PMIDs:
23807564

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

REPAGLINIDE Primary Drug Name

Drug Info:

Year of Approval 1997

Drug Class hypoglycemic agents

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

CHEMBL1272 ChEMBL Drug ID

Alternate Names:

D0N5YA TTD Drug ID